Effect of probiotics, prebiotics and synbiotics for chronic bronchitis or chronic obstructive pulmonary disease

Abstract

Background: Probiotics, prebiotics and synbiotics have been widely used in the treatment of respiratory diseases, but their clinical efficacy for treating chronic bronchitis (CB) or chronic obstructive pulmonary disease (COPD) has not been well studied. Methods: The following electronic databases will be searched for eligible randomized controlled trials: the Cochrane Library, EMBASE, MEDLINE, PubMed, Scopus, the Web of Science, the China National Knowledge Infrastructure, the Wanfang database, and the China Science and Technology Journal database (VIP Information Network). We will search these electronic databases weekly and extract relevant data from their inception dates until September 30, 2020. Risk of publication bias will be evaluated by the Cochrane Handbook for Systematic Reviews of Interventions. Data synthesis will be conducted using Review Manager (RevMan) version 5.3 software. Sensitivity and quality of evidence analyses will be conducted. Results: This systematic review and meta-analysis will provide a high-quality synthesis from existing evidence for estimating the efficacy and safety of probiotics, prebiotics and synbiotics in the treatment of CB or COPD. Conclusion: This systematic review and meta-analysis will provide reliable and accurate evidence to guide the use of probiotics, prebiotics and synbiotics in the treatment of CB or COPD. Registration OSF registration number: DOI 10.17605/OSF.IO/SP35M.

Lung Damage Prevention of Ethanolic Extract of Propolis and Synbiotics in Inhalation Anthrax Model

“…This result is relevant to a study that showed that EEP is potentially enough to treat lung inflammation by reducing the inflammation process and oxidative stress oxidative [24]. In contrast, the efficacy and safety of synbiotics in treating some lung diseases are still questionable [25].…”

The effect of budesonide combined with bifidobacteria and lactobacilli on lung function and gut microbiota of patients with chronic obstructive pulmonary disease

“…Pei C et al 14 confirmed that comprehensive intervention with probiotics based on conventional drug therapy for COPD can further alleviate patients' clinical symptoms and improve the overall therapeutic effect. Karim A et al 15 also pointed out that adding probiotics to the routine treatment regimen of COPD patients not only improves their walking speed and grip strength, but also has a positive effect on downregulating the expression of C-reactive proteins and reducing the degree of inflammation in the body.…”

Probiotics combined with Budesonide and Ipratropium bromide for chronic obstructive pulmonary disease: A retrospective analysis

“…[ 21 ] It has been confirmed that the auxiliary intervention of probiotics based on symptomatic treatment of COPD can improve the muscle function, strength, and body function of COPD patients by stabilizing neuromuscular and regulating intestinal permeability. [ 20 , 21 ] A recent meta-analysis by Pei C et al [ 22 ] confirmed the important role of probiotics in alleviating clinical symptoms, improving lung function, and ensuring good disease outcomes in patients with COPD. Jamarkandi SA et al [ 23 ] also confirmed that there are many risk factors that can cause gut microbiota imbalance and intestinal microecology disorder in the pathogenesis and progression of COPD, resulting in increased secretion and synthesis of endotoxins, but the above problems can be improved by the application of probiotics.…”